AlphAIAlphAI — Financial news for AI agents
Zacks CommentaryNOV 73 min read$DH

Definitive Healthcare Corp. (DH) Beats Q3 Earnings and Revenue Estimates

Definitive Healthcare (DH) delivered earnings and revenue surprises of +16.67% and +1.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Original reporting
Zacks Commentary · Zacks Equity Research
Published Nov 7, 2025, 1:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 7, 2025, 3:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Definitive Healthcare Corp. (DH) Beats Q3 Earnings and Revenue Estimates — source image
Source · www.zacks.com
Decision brief

The 30-second read

$DHBullishMed
01

Why it matters

The earnings beat suggests improved financial health, potentially leading to stock price appreciation.

02

Market read

The positive earnings report enhances DH's short-term trading prospects, especially within healthcare and technology sectors.

03

What to watch

Potential macroeconomic headwinds or sector-specific risks could offset positive earnings impact.

Timing: Immediate, as earnings reports influence short-term trading.

Background

Definitive Healthcare reported Q3 earnings that exceeded estimates, indicating operational strength.

Company-level read

Ticker impact

$DHBullishHigh confidence
Context

Primary focus of the news due to earnings beat.

Expected impact

Moderate upward movement expected in the short term.

Evidence & confidence

The earnings beat significantly exceeds analyst expectations, suggesting strong operational performance. The positive sentiment and historical market reactions to earnings surprises support this outlook.

Market effects

Sector

Positive sentiment for healthcare and technology sectors due to strong earnings.

Regional

Potential uplift in regional healthcare stocks; limited impact on broader markets.

Global

Moderate, as healthcare sector performance can influence global health tech trends.

Counterpoint

What could challenge this read

Earnings beat may be a short-term anomaly; caution advised before overextending positions.

Key entities

  • Company
    Definitive Healthcare

    A healthcare analytics and data provider.

Read at source← All news

Related articles

SEP 4
$IONSHighAI 9/10

Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals

Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.

rttnews.com3 min
SEP 3
$DHMedAI 8/10

Advent Proposed $1.02 Cash Take-Private of Definitive Healthcare:

Definitive Healthcare Corp. (DH) received a non-binding take-private proposal from Advent International for $1.02 per share. The offer is subject to review by a special committee and requires founder Jason Krantz's equity rollover. No binding agreement exists yet, and Advent may withdraw or modify the proposal.

hedgeco.net1 min
SEP 2
$DHHigh

Definitive Healthcare stock surges 13% on Advent buyout offer

Definitive Healthcare (NASDAQ:DH) shares rose 13% after Advent International offered to buy the company for $1.02 per share, a 36% premium over its 60-day average. The deal requires approval from a special committee and Jason Krantz's stock rollover. Definitive Healthcare also appointed Clay Ritchey as CEO, replacing Kevin Coop.

investing.com2 min
AUG 18
$DHMedAI 8/10

Definitive Healthcare (DH) Q2 2026 Earnings Call

Definitive Healthcare (DH) reported Q2 FY26 revenue of $55.2 million, down 9% year over year, with adjusted EBITDA of $14.6 million and net dollar retention improving for a second straight quarter. Subscription revenue fell 9% to $52.8 million. Full-year guidance: revenue $220-$222 million and adjusted EBITDA $57-$59 million; Q3 revenue $54-$55 million.

fool.com6 min
AUG 10
$DHHigh

Definitive Healthcare Corp. (DH): Results of Operations and Financial Condition

Definitive Healthcare Corp. (DH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Definitive Healthcare Reports Financial Results for Second Quarter 2026 Second Quarter Revenue Within Guidance Range; Profit Surpasses Expectations Framingham, MA (August 10, 2026) – Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH),

SEC EDGAR 8-K6 min